Personalized glycemic response led digital therapeutics program improves time in range in a period of 14 days.

Ritika Verma, Shefali Bhardwaj, Tejal Lathia, Sanjay Kalra, Ruchira Ranadive, Snehal Tanna, Mahesh Padsalge, Archana Juneja, Kirti Samundra, Piya Ballani Thakkar, Vandana Jain, Vishal Kini, Sneha Kothari, Saimala Guntur, Shilpa Joshi, Arbinder Singal
Author Information
  1. Ritika Verma: Fitterfly Healthtech Pvt Ltd, Akshar Blue Chip Corporate Park Turbhe MIDC, Navi Mumbai, 400705 India.
  2. Shefali Bhardwaj: Fitterfly Healthtech Pvt Ltd, Akshar Blue Chip Corporate Park Turbhe MIDC, Navi Mumbai, 400705 India.
  3. Tejal Lathia: Apollo Hospital, Navi Mumbai, 400614 India.
  4. Sanjay Kalra: Bharti Research Institute of Diabetes & Endocrinology, Haryana, India.
  5. Ruchira Ranadive: Fitterfly Healthtech Pvt Ltd, Akshar Blue Chip Corporate Park Turbhe MIDC, Navi Mumbai, 400705 India.
  6. Snehal Tanna: Jupiter Hospital, Thane, India.
  7. Mahesh Padsalge: Diabecare Diabetes & Thyroid Clinic, Navi Mumbai, India.
  8. Archana Juneja: Kokilaben Hospital, Mumbai, India.
  9. Kirti Samundra: Diabetes Care Clinic, Navi Mumbai, India.
  10. Piya Ballani Thakkar: Bombay Hospital, Marine Lines, Mumbai, India.
  11. Vandana Jain: Advanced Eye Hospital and Institute, Navi Mumbai, India.
  12. Vishal Kini: Care n Cure Speciality Clinic, Navi Mumbai, India.
  13. Sneha Kothari: Global Hospitals, Mumbai, India.
  14. Saimala Guntur: Fitterfly Healthtech Pvt Ltd, Akshar Blue Chip Corporate Park Turbhe MIDC, Navi Mumbai, 400705 India.
  15. Shilpa Joshi: Fitterfly Healthtech Pvt Ltd, Akshar Blue Chip Corporate Park Turbhe MIDC, Navi Mumbai, 400705 India.
  16. Arbinder Singal: Fitterfly Healthtech Pvt Ltd, Akshar Blue Chip Corporate Park Turbhe MIDC, Navi Mumbai, 400705 India.

Abstract

Background: Lifestyle modification is an integral aspect for the management of type 2 diabetes (T2D). However, it is difficult to ensure the accuracy of personalized lifestyle advice. The study aims to analyse the real-world effectiveness of personalized glycemic response based Diabefly-Pro digital therapeutics for better glycemic control.
Methods: Data from continuous glucose monitoring (CGM) of 64 participants with T2D was analysed. All participants were provided with modified lifestyle plan based on their personalized glycemic response. The CGM data was analysed for a period of 7 days, before and after the introduction of modified lifestyle plan. Primary outcome of the study was change in time in range (TIR). Secondary outcomes of the study were change in mean blood glucose, time above range (TAR), time below range (TBR) and glucose management indicator (GMI).
Results: Significant improvement in glycemic control was observed after the introduction of personalized lifestyle plan. Median reduction in mean blood glucose was from 139.5 (118.3 to 169.3) mg/dL to 122.0 (101.5 to 148.8) mg/dL ( < 0.0001). TIR and GMI improved from 70.50 (50.75 to 83.50) % to 75.00 (58.25 to 89.00) % ( = 0.0001) and 6.64 (6.13 to 7.35) % to 6.23 (5.74 to 6.86) % ( < 0.0001) respectively. TAR reduced significantly from 17.00 (4.25 to 38.0) % to 6.00 (1.25 to 26.0) % ( < 0.0001). No significant increase in TBR was observed ( = 0.198).
Conclusion: Personalized glycemic response-based Diabefly-Pro digital therapeutics program was effective in achieving better glycemic control in people with T2D.

Keywords

References

  1. Diabetes Care. 2019 Mar;42(3):400-405 [PMID: 30352896]
  2. Lancet. 1998 Sep 12;352(9131):837-53 [PMID: 9742976]
  3. J Med Internet Res. 2020 Aug 28;22(8):e21778 [PMID: 32856597]
  4. J Acad Nutr Diet. 2018 Feb;118(2):343-353 [PMID: 29389511]
  5. J Med Internet Res. 2019 Oct 9;21(10):e15814 [PMID: 31599740]
  6. JAMA. 2012 Dec 19;308(23):2489-96 [PMID: 23288372]
  7. Diabetes. 2005 Jan;54(1):1-7 [PMID: 15616004]
  8. J Med Internet Res. 2015 Apr 10;17(4):e92 [PMID: 25863515]
  9. World J Diabetes. 2019 Jun 15;10(6):341-349 [PMID: 31231457]
  10. J Pak Med Assoc. 2021 Feb;71(2(A)):562-563 [PMID: 33819253]
  11. J Acad Nutr Diet. 2017 Oct;117(10):1659-1679 [PMID: 28533169]
  12. Diabetes Care. 2013 Jun;36(6):1541-6 [PMID: 23275370]
  13. JMIR Diabetes. 2018 Feb 14;3(1):e4 [PMID: 30291074]
  14. Lancet Diabetes Endocrinol. 2020 Jul;8(7):571 [PMID: 32422126]
  15. Diabetes Care. 2019 Jan;42(Suppl 1):S46-S60 [PMID: 30559231]
  16. Diabetes Care. 2015 Jul;38(7):1372-82 [PMID: 26048904]
  17. Diabetes Res Clin Pract. 2019 Nov;157:107843 [PMID: 31518657]
  18. Diabetes Technol Ther. 2014 Sep;16(9):596-603 [PMID: 25101698]
  19. Gesundheitswesen. 2017 Aug;79(8-09):619-626 [PMID: 26516725]
  20. Int J Pediatr Endocrinol. 2012 Oct 26;2012(1):28 [PMID: 23098076]
  21. BMJ. 2007 Feb 10;334(7588):299 [PMID: 17237299]
  22. J Assoc Physicians India. 2004 Jun;52:468-74 [PMID: 15645957]
  23. Diabetes Care. 2020 Jan;43(1):250-260 [PMID: 31806649]
  24. N Engl J Med. 2002 Feb 7;346(6):393-403 [PMID: 11832527]
  25. Diabetes Care. 2018 Nov;41(11):2275-2280 [PMID: 30224348]
  26. BMJ Open Diabetes Res Care. 2019 Jul 14;7(1):e000654 [PMID: 31413840]
  27. Diabetes Care. 2019 Aug;42(8):1593-1603 [PMID: 31177185]

Word Cloud

Created with Highcharts 10.0.0glycemic0%glucose6personalizedlifestyleresponsetherapeuticstimerange000100T2Dstudydigitalcontrolplan5<5025PersonalizedmanagementbasedDiabefly-ProbettermonitoringCGM64participantsanalysedmodifiedperiod7daysintroductionchangeTIRmeanbloodTARTBRGMIobserved3mg/dL75=programBackground:Lifestylemodificationintegralaspecttype2diabetesHoweverdifficultensureaccuracyadviceaimsanalysereal-worldeffectivenessMethods:DatacontinuousprovideddataPrimaryoutcomeSecondaryoutcomesindicatorResults:SignificantimprovementMedianreduction1391181691221011488improved708358891335237486respectivelyreducedsignificantly17438126significantincrease198Conclusion:response-basedeffectiveachievingpeopleledimproves14ContinuousDiabetesDigital

Similar Articles

Cited By